ADCLEC.syn1 CAR T cells

ADCLEC.syn1 CAR T cells are a novel, investigational chimeric antigen receptor (CAR) T-cell therapy designed for the treatment of relapsed or refractory acute myeloid leukemia (AML). This therapy involves genetically modifying patient-derived T lymphocytes to express a combinatorial CAR that targets both CLEC12A and ADGRE2, two cell surface antigens highly co-expressed on AML blasts but with limited overlap in normal tissues. The dual targeting is intended to enhance anti-leukemic efficacy while minimizing off-tumor toxicity. Preclinical studies have demonstrated that ADCLEC.syn1 can induce complete and durable remissions in AML models, outperforming conventional single-target CD33-CAR therapies by preventing antigen escape and maintaining activity even in the presence of normal bystander myeloid cells. The platform was developed using bicistronic gamma-retroviral vectors to optimize scFv affinities and signaling domains for selective cytolysis of malignant over normal hematopoietic cells. Clinical development is ongoing, with Phase 1 trials evaluating safety, dosing, and preliminary efficacy in adults with relapsed or refractory AML[3][4][5][6].

Other names

CLEC12A-targeting CCR/anti-ADGRE2 CAR T cells